In Alzheimer’s disease, a protein (peptide) forms clumps in the brain and causes sufferers to lose their memory.
In a new study, researchers found a new treatment method that increases the body’s own degradation of the building blocks that lead to these protein clumps.
The research was conducted by a team at Uppsala University
In Alzheimer’s disease, the peptide amyloid-beta begins to form clumps in the brain. This process is called aggregation and the clumps so created are called aggregates.
The treatment methods for Alzheimer’s disease that are currently in clinical trials are attempts to bind to these disease-causing aggregates.
But they are unable to bind to the smallest aggregates, which many now believe are the most toxic to neurons.
The new treatment method could degrade the building blocks from which these aggregates form before they have a chance to aggregate.
This treatment method therefore reduces the formation of all types of aggregates.
It has long been known that the peptide somatostatin can activate the body’s own degradation of amyloid-beta, which is the peptide that forms the aggregates.
However, it has not been possible to use somatostatin as a drug in the past because it has a very short half-life in the blood of only a few minutes, and does not cross the blood-brain barrier into the brain where the aggregates are formed.
So to be able to use somatostatin as a treatment, the team fused it to a brain transport protein which allows the somatostatin to enter the brain. This has proved very effective.
In the study, the researchers saw the greatest effect in the hippocampus, the part of the brain that forms memories and the first part to be affected by Alzheimer’s disease.
They say the fact that they have seen that the effect is most evident in the hippocampus, in particular, is very good.
The hope is that this method will be able to act in a very targeted way and have few side effects, which have been a problem in other studies.
One author of the study is Fadi Rofo at the Department of Pharmaceutical Biosciences.
The study is published in Theranostics.
Copyright © 2020 Knowridge Science Report. All rights reserved.
